Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc. - Monday November 17, 2:49 am Eastern Time
Fortovase, which was recently cleared for marketing by the U.S. Food and Drug Administration, is currently under review by regulatory authorities in the European Union and other countries, Roche said in a statement.
Saquinavir mesylate was the first protease inhibitor available for the treatment of HIV disease with the brand name Invirase and ongoing development has lead to the new formula that is being introduced under the name of Fortovase.
Compared with the current, hard gel formula of saquinavir, Fortovase can be given in dosages that are eight to 10 times higher.
"Fortovase is a more potent drug that Invirase because the bioavailability and, more important, the drug exposure (the amount of drug absorbed in the bloodstream), results in a significant increase in anti-viral activity," Roche said.
-- e-mail: zurich.newsroom@reuters.com
Tel: +41 1 631 7340
971117
RE971109
Copyright © 1997 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .